Can cagrilintide be used alone to lose weight?

In trials, yes. In the 68-week REDEFINE 1 phase 3 study, cagrilintide alone produced 11.8% weight loss, compared with 2.3% on placebo, and Novo Nordisk is starting a dedicated phase 3 program called RENEW. That was smaller than the 20.4% seen with CagriSema, its combination with semaglutide, in the same trial. The 11.8% figure comes from a sub-analysis presented at the EASD congress in 2025.

Cagrilintide isn’t approved alone or in combination with semaglutide. For labs studying amylin signaling on its own, eloralintide offers a more selective tool: in its 48-week phase 2 trial, eloralintide alone reached 20.1% weight loss at 9 mg, though the trials differed in design and length. Read our research purposes only policy, then Shop eloralintide.